Recursion
41 S. Rio Grande Street
Salt Lake City
Utah
84101
United States
Tel: 801-587-1629
Fax: 801-581-7895
Website: https://www.recursion.com/
Email: info@recursion.com
About Recursion
Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to radically improve the lives of patients and industrialize drug discovery. Our team is working to solve some of the hardest, most meaningful problems facing human health today.
Recursion is proudly headquartered in Salt Lake City, Utah with offices in Toronto, Montreal and Milpitas, California. We're working to solve some of the most meaningful problems facing human health today. Come do the most impactful work of your career at a company that prioritizes belonging, collaboration and career development.
Recursion 101: A Biotechnology Company Industrializing Drug Discovery
88 articles about Recursion
-
Bayer and Recursion focus research collaboration on Oncology
11/9/2023
Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, announced that they have updated the focus of their research collaboration to precision oncology.
-
Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results
11/9/2023
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, reported business updates and financial results for its third quarter ending September 30, 2023.
-
Recursion Announces Data Collaboration Deal with Tempus, Top 50 Supercomputer Ambition Powered by NVIDIA, and Updated Focus of Collaboration with Bayer to Precision Oncology
11/9/2023
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced two significant updates with their collaborators NVIDIA and Bayer, and a new collaboration with Tempus Labs as it creates infrastructure and expands its ambitions and scope in the precision oncology space.
-
Recursion to Participate in Upcoming November 2023 Investor Conference
11/2/2023
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced its participation in the following investor conference:
-
Recursion to Participate in Upcoming September 2023 Investor Conferences
9/5/2023
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced its participation in the following investor conferences.
-
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
8/8/2023
Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates and financial results for its second quarter ending June 30, 2023.
-
Recursion to Participate in Upcoming August 2023 Investor Conference
8/1/2023
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced its participation in the following investor conference.
-
Recursion Announces Collaboration and $50 Million Investment from NVIDIA to Accelerate Groundbreaking Foundation Models in AI-Enabled Drug Discovery
7/12/2023
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced a $50 million investment by NVIDIA, which was executed as a private investment in public equity (PIPE).
-
The tech giant is investing $50 million in the Utah-based biotech to accelerate development of its AI foundation models for drug discovery.
-
Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
6/13/2023
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced the full enrollment of its Phase 2 SYCAMORE clinical trial evaluating REC-994, a potentially first-in-class, orally bioavailable small molecule for the treatment of CCM.
-
Recursion to Participate in Upcoming June 2023 Investor Conferences
6/1/2023
Recursion, a clinical stage TechBio company decoding biology to industrialize drug discovery, announced its participation in the following investor conferences:
-
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
5/16/2023
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced it has appointed David Mauro, M.D., Ph.D, as its Chief Medical Officer.
-
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
5/8/2023
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its first quarter ending March 31, 2023.
-
To help with your job search, here are 10 biopharma companies hiring for Artificial Intelligence and Machine Learning (AI/ML) roles now.
-
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2022 Financial Results
2/27/2023
Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery, today reported business updates and financial results for its fourth quarter and fiscal year ending December 31, 2022.
-
Recursion to Participate in Upcoming Investor Conference - February 1, 2023
2/1/2023
Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following investor conference.
-
Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day
1/26/2023
Recursion announced the public release of MolRec™ - one of its many interactive internal tools to explore the company's proprietary maps of biology and chemistry.
-
Recursion to Participate in Upcoming January 2023 Investor Conferences
12/20/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following investor conferences.
-
Recursion Provides Business Updates and Reports Third Quarter 2022 Financial Results
11/8/2022
Recursion (Nasdaq: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today reported business updates and financial results for its third quarter ending September 30, 2022.
-
Recursion to Participate in Upcoming November 2022 Investor Conferences
11/2/2022
Recursion, the clinical-stage biotechnology company industrializing drug discovery by decoding biology, announced its participation in the following November 2022 investor conferences.